Yong Wang MBA Chairman
Yong Wang is the Chairman of VcanBio Center for Translational Biotechnology and vice chairman of VcanBio Cell& Gene Engineering Co., Ltd.(Parent Company). Mr. Wang also serves as the Chairman and Chief Executive Officer of several VcanBio subsidiaries in China, including Union Stem Cell&Gene Engineering Co., Ltd., Beijing VcanBio Investment Corp., Shanghai HeZeTongJi Biotech Co., Ltd. From 2012 to 2014, he was the Chairman of the Board of Alliancells Bioscience Co., Ltd., a pioneer company in China developing clinical drug, stem cell anti-aging product, and stem cell cosmetic product. Prior to that, he served as the General Manager of Hongkan Investment Co., Ltd.
Mr. Wang earned an MBA degree at Nankai University in China.
Shi-Jiang (John) Lu Ph.D, MPH President & CEO
Shi-Jiang (John) Lu is currently the President and CEO of VcanBio CTB. and HebeCell Corporation. Before joining VcanBio Center for Translational Biotechnology and HebeCell, John was the Senior Director of Research at Ocata Therapeutics, which was recently acquired by Astellas, the 2nd largest pharmaceutical company of Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. John has been conducting translational researches and novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. The goal of his research is to generate hESC/iPSC-derived products for the treatment of human diseases. He has extensive experience in process development and large-scale production of human pluripotent stem cell derivatives for clinical applications.
John received his Ph.D degree in Oncology and Cancer Biology from University of Toronto/Ontario Cancer Institute, an M.P.H degree from Columbia University, an M.S. degree in Oncology from Peking Union Medical College and a B.S. degree in Biochemistry from Wuhan University.
Allen Feng Ph.D Chief Scientific Officer
Dr. Allen Feng is the Chief Scientific Officer of VcanBio CTB and HebeCell Corp. Prior to joining VcanBio, he was the Director of Cell Biology of Semma Therapeutics, where Dr. Feng played a key role in the successful establishment of the process development operation. Prior to Semma, Dr. Feng worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore (a US subsidiary of Merck, KGaA). Before joining Millipore, Dr. Feng was Director and Senior Scientist at Advanced Cell Technology (later became Ocata Therapeutics and Astellas). At Advanced Cell Technology, Dr. Feng was the major contributor and inventor of several key discoveries such as the patented Hemangioblast technology (published in Nature Methods); generation of donorless red blood cells (published in Blood); and generation of HLA-negative functional platelets from human pluripotent stem cells (published in Stem Cell Reports).
Dr. Feng graduated with a Ph.D and an M.S. degree from Institute of Zoology at Chinese Academy of Sciences. He earned his B.S. degree from Beijing Normal University. He was the Associate Professor and the Deputy Director of the State Key Laboratory of Reproductive Biology in Chinese Academy of Sciences. Dr. Feng received the prestigious award of Wu Jie-ping Medical Research Award and the Paul Janssen Pharmaceutical Research Award in 1995, as well as the Fellowship of Marie-Curie of the European Union and the Wellcome Trust (U.K)
Meng (Marie) Zhang Ph.D Vice President
Dr. Meng (Marie) Zhang joined VcanBio CTB in April of 2016 as Vice President of Preclinical Development. Prior to joining VcanBio CTB, she served as a leading scientist and team manager on the research and development of the advanced platform for biomolecule detection and clinical diagnostics in US Genomics, a developer of single-molecule technologies for biodefense and clinical diagnostics, and later in NABsys to develop solid-state nanodetectors for high definition whole genome mapping.
With more than 15 years’ experience in the biotech industry, Dr. Zhang is an expert on process development and product quality control, specializing in single biomolecule and biomarker analysis, protein chemistry and cell biology. Dr. Zhang also has experience in iPSC differentiation toward endothelial and hematopoietic cells, epigenetic modification, and gene functionality regulation.
Dr. Zhang received her Ph. D degree in biochemistry & molecular medicine from University of Massachusetts Medical School and a B. S degree in pharmaceuticals from Shanghai Medical College at Fudan University.
Yi Chen Ph.D Treasurer and Secretary
Dr. Yi (Eric) Chen joined Zhongyuan Union (VcanBio, the parent company in Tianjin, China) in April of 2015 and was heavily involved in establishing the VcanBio USA, serving as the Vice President ever since it was founded in June of 2015. Prior to that, he was one of the key research scientists at the National Center for Adaptive Neurotechnologies (the first in the world to focus entirely on adaptive neurotechnologies and the hub of a multifaceted NIH-funded research and development program) and Laboratory of Neural Injury and Repair at Wadsworth Center of the New York State Department of Health & State University of New York at Albany.
Dr. Chen began his research career 15 years ago as a graduate student and has an extensive background in the fields of neurophysiology and cell biology, proficient in planning, coordinating, and executing complex projects in electrophysiology and neural studies, offering significant contributions to advance key investigations. His research involved exploring regenerative approaches in lab animals to treat neural deficits, with specific training and expertise in behavioral, functional and electrophysiological studies of neuronal plasticity and repair in the spinal cord.
Dr. Chen received his Ph.D. degree in Physiology and Cell Biology from the Ohio State University and a B.S degree in Clinical Medicine from Nanjing Medical University.